Kyntra Bio, Inc. (KYNB)
8.55
+0.06
(+0.71%)
USD |
NASDAQ |
Sep 04, 16:00
8.55
0.00 (0.00%)
After-Hours: 20:00
Kyntra Bio Research and Development Expense (Quarterly) : 6.821M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.821M |
| March 31, 2026 | 7.566M |
| December 31, 2025 | 7.268M |
| September 30, 2025 | 1.209M |
| June 30, 2025 | 5.865M |
| March 31, 2025 | 9.175M |
| December 31, 2024 | 6.87M |
| September 30, 2024 | 19.97M |
| June 30, 2024 | 32.36M |
| March 31, 2024 | 36.49M |
| December 31, 2023 | 48.71M |
| September 30, 2023 | 61.19M |
| June 30, 2023 | 95.48M |
| March 31, 2023 | 74.49M |
| December 31, 2022 | 61.63M |
| September 30, 2022 | 75.18M |
| June 30, 2022 | 70.96M |
| March 31, 2022 | 89.02M |
| December 31, 2021 | 113.92M |
| September 30, 2021 | 75.88M |
| June 30, 2021 | 122.57M |
| March 31, 2021 | 74.68M |
| December 31, 2020 | 78.13M |
| September 30, 2020 | 58.48M |
| June 30, 2020 | 61.41M |
| Date | Value |
|---|---|
| March 31, 2020 | 54.90M |
| December 31, 2019 | 56.80M |
| September 30, 2019 | 49.96M |
| June 30, 2019 | 52.01M |
| March 31, 2019 | 50.50M |
| December 31, 2018 | 70.28M |
| September 30, 2018 | 56.44M |
| June 30, 2018 | 52.14M |
| March 31, 2018 | 56.97M |
| December 31, 2017 | 52.47M |
| September 30, 2017 | 50.34M |
| June 30, 2017 | 46.98M |
| March 31, 2017 | 46.73M |
| December 31, 2016 | 50.61M |
| September 30, 2016 | 40.56M |
| June 30, 2016 | 52.39M |
| March 31, 2016 | 43.65M |
| December 31, 2015 | 59.92M |
| September 30, 2015 | 52.07M |
| June 30, 2015 | 51.56M |
| March 31, 2015 | 50.54M |
| December 31, 2014 | 51.26M |
| September 30, 2014 | 40.62M |
| June 30, 2014 | 33.27M |
| March 31, 2014 | 25.65M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vericel Corp. | 7.493M |
| Capricor Therapeutics, Inc. | 28.57M |
| ARS Pharmaceuticals, Inc. | 4.698M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |